Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Merger or Acquisition (May 2013)
17 slides from Anagenics's merger presentation, May 8, 2013
Slide 1: ASX Announcement: CEO Presentation, Acquisition of Advangen Inc., Japan
ASX ANNOUNCEMENT CEO PRESENTATION: ACQUISITION OF ADVANGEN INC., JAPAN SYDNEY, Wednesday, 8 May 2013: Cellmid Limited (ASX: CDY) provides a copy of the presentation given by the CEO, Maria Halasz, in relation to the strategic acquisition of Advangen Inc. Japan. End Contact: Maria Halasz, CEO T +612
Slide 2: Acquisition of Advangen Inc. Japan: A Strategic Deal to Boost Revenues
ACQUISITION OF ADVANGEN INC. JAPAN A STRATEGIC DEAL TO BOOST REVENUES May 2013 Maria Halasz CEO
Slide 3: Forward-looking statements
This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this presentation. Actual res
Slide 4: Cellmid Business Structure
Business Structure Cellmid OTC Diagnostics Therapeutics Hair growth products Cancer biomarker Midkine Midkine Multiple products antibodies protein FGF‐5 inhibitors Anti‐ AMI inflammatory Lung Cancer (Quest) Midkine Cancer for hair growth Bladder Cancer: CxBladder (Pacific Edge) 3
Slide 5: Market opportunity for hair growth products
Market opportunity for hair growth products • Minoxidil sales: $300M annually (Newport Horizon) • Advangen’s products are: • Clinically validated • No reported side effects (700,000 bottles sold in Japan in 5 years) • Suitable for men and women • 98% of website users love the FGF‐5 inhibitor product
Slide 6: Midkine promotes hair growth in preclinical models
How Cellmid got involved in this lucrative market… Midkine promotes hair growth in preclinical models Jun 2009 Midkine is found to promote hair growth in pre‐clinical animal models Late 2009 Cellmid to fund research from revenues of scientifically validated OTC hair growth product (Advangen) Day 1 D
Slide 7: Cellmid in-licensed Advangen's technology in 2010
Cellmid in‐licensed Advangen’s technology in 2010 Nov 2010 Signed distribution and manufacturing agreement with Advangen Inc. (Australia, EU and USA) 2011 Transfer of FGF‐5 technology to Australia Brand development (évolis) Product positioning (OTC pharmacy) 2012 TGA listing GMP manufacture Launch i
Slide 8: FGF-5 inhibitor technology works: promotes hair growth in clinical study
FGF‐5 inhibitor technology works: it promotes hair growth and reduces hair loss in clinical study Quantitative assessment • Rate of hair growth increased by 21% • Hair loss reduced by 35% Qualitative assessment • 74% found the treatment beneficial for hair growth 7
Slide 9: Advangen Inc.
Advangen Inc. • Established in 2002 with science developed at the AIST, Japan • VC funded since 2002 • Set up to commercialise FGF‐5 inhibitor hair growth technology • Launched first product in 2007 • Sold 700,000 bottles since launch • Cellmid relationship since late 2009 8
Slide 10: Highly strategic acquisition with multiple upsides
Highly strategic acquisition with multiple upsides • Ownership of FGF‐5 technology globally • Access to established Japanese market – scope for growth • Large new markets such as China, Taiwan, Singapore, Malaysia • Chinese import permits for Jo‐Ju and Lexilis brands of lotions and shampoos • Pricin
Slide 11: Deal summary
Deal summary • 100% of Advangen Inc shares acquired from current owners • $1.2M cash and 55M CDY shares • Shares issued at 5 cents each • Shares escrowed for up to 12 months 10
Slide 12: Distribution
Distribution Continue to expand pharmacy distribution (evolis) Australia Set up and grow salon distribution (Jo‐Ju) Launch global online sales program (evolis, English) Expand direct distribution (Andeprong) Japan Set up OTC distribution (evolis) Cellmid Website sales launch (Japanese) (Advangen Lim
Slide 13: Diagnostics: Strong product pipeline with revenues in 2013
Diagnostics: Strong product pipeline with revenues in 2013 PRECLINICAL CLINICAL MARKET CxBladder for bladder cancer (Pacific Edge) MK‐ELISA (research market) Lung cancer diagnostic (Quest) MK metastatic colorectal diagnostic MK as a co‐marker in prostate cancer MK as a marker in glioblastoma MK as a
Slide 14: Therapeutic pipeline is on track to clinic in 2015
Therapeutic pipeline is on track to clinic in 2015 Animal studies Disease reduced by MK treatment? DISEASE Reduced Clinical indication disease in RNAi mAbs and/or MK Inhibitors MK‐/‐? YES Osteosarcoma Cancer YES (multiple YES Glioma/glioblastoma cancers) Metastasising carcinomas Abdominal surgery Su
Slide 15: The right team: track record in execution and delivery
The right team: track record in execution and delivery Dr David King, Chairman Graeme Kaufman, Non‐executive director Martin Rogers, Non‐executive director Maria Halasz, CEO and Managing Director Darren Jones, Head of Product Development Emma Chen, General Manager Advangen (Australia) 14
Slide 16: Summary
Summary Significant near term revenue – hair growth products and diagnostics High value product pipeline – diagnostic, therapeutic, hair growth The right team with strong track record in execution and delivery 15
Slide 17: Thank you
Thank you www.cellmid.com.au Maria Halasz CEO (612) 9221 6830 halasz@cellmid.com.au 16